JP2007508390A - ムスカリン性アセチルコリン受容体アンタゴニスト - Google Patents

ムスカリン性アセチルコリン受容体アンタゴニスト Download PDF

Info

Publication number
JP2007508390A
JP2007508390A JP2006535591A JP2006535591A JP2007508390A JP 2007508390 A JP2007508390 A JP 2007508390A JP 2006535591 A JP2006535591 A JP 2006535591A JP 2006535591 A JP2006535591 A JP 2006535591A JP 2007508390 A JP2007508390 A JP 2007508390A
Authority
JP
Japan
Prior art keywords
bicyclo
endo
diphenyl
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006535591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007508390A5 (cg-RX-API-DMAC7.html
Inventor
ヤーコプ・ブッシュ−ペーターセン
マイケル・アール・パロビッチ
ワン・ゼホン
ヤン・ホンシン
チュ・チョンジェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2007508390A publication Critical patent/JP2007508390A/ja
Publication of JP2007508390A5 publication Critical patent/JP2007508390A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2006535591A 2003-10-14 2004-10-12 ムスカリン性アセチルコリン受容体アンタゴニスト Pending JP2007508390A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51100903P 2003-10-14 2003-10-14
PCT/US2004/033638 WO2005037280A1 (en) 2003-10-14 2004-10-12 Muscarinic acetycholine receptor antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2007201719A Division JP2007314567A (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201718A Division JP4796552B2 (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト

Publications (2)

Publication Number Publication Date
JP2007508390A true JP2007508390A (ja) 2007-04-05
JP2007508390A5 JP2007508390A5 (cg-RX-API-DMAC7.html) 2007-09-20

Family

ID=34465175

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2006535591A Pending JP2007508390A (ja) 2003-10-14 2004-10-12 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201719A Pending JP2007314567A (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201718A Expired - Fee Related JP4796552B2 (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2011109756A Expired - Fee Related JP5450509B2 (ja) 2003-10-14 2011-05-16 ムスカリン性アセチルコリン受容体アンタゴニスト

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2007201719A Pending JP2007314567A (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007201718A Expired - Fee Related JP4796552B2 (ja) 2003-10-14 2007-08-02 ムスカリン性アセチルコリン受容体アンタゴニスト
JP2011109756A Expired - Fee Related JP5450509B2 (ja) 2003-10-14 2011-05-16 ムスカリン性アセチルコリン受容体アンタゴニスト

Country Status (34)

Country Link
US (3) US7276521B2 (cg-RX-API-DMAC7.html)
EP (1) EP1677795B1 (cg-RX-API-DMAC7.html)
JP (4) JP2007508390A (cg-RX-API-DMAC7.html)
KR (3) KR20080067023A (cg-RX-API-DMAC7.html)
CN (3) CN101230061A (cg-RX-API-DMAC7.html)
AP (3) AP1828A (cg-RX-API-DMAC7.html)
AR (1) AR046103A1 (cg-RX-API-DMAC7.html)
AT (1) ATE494285T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004281724B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415361A (cg-RX-API-DMAC7.html)
CA (1) CA2542657C (cg-RX-API-DMAC7.html)
CY (1) CY1111364T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004030930D1 (cg-RX-API-DMAC7.html)
DK (1) DK1677795T3 (cg-RX-API-DMAC7.html)
EA (3) EA009899B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066468A (cg-RX-API-DMAC7.html)
ES (1) ES2358673T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110232T1 (cg-RX-API-DMAC7.html)
IL (2) IL174843A0 (cg-RX-API-DMAC7.html)
IS (1) IS2918B (cg-RX-API-DMAC7.html)
MA (1) MA28110A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004244A (cg-RX-API-DMAC7.html)
MY (1) MY143366A (cg-RX-API-DMAC7.html)
NO (1) NO20062042L (cg-RX-API-DMAC7.html)
NZ (2) NZ546312A (cg-RX-API-DMAC7.html)
OA (1) OA13316A (cg-RX-API-DMAC7.html)
PE (1) PE20050963A1 (cg-RX-API-DMAC7.html)
PL (1) PL1677795T3 (cg-RX-API-DMAC7.html)
PT (1) PT1677795E (cg-RX-API-DMAC7.html)
SG (1) SG147436A1 (cg-RX-API-DMAC7.html)
SI (1) SI1677795T1 (cg-RX-API-DMAC7.html)
TW (3) TWI409060B (cg-RX-API-DMAC7.html)
UA (2) UA89734C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005037280A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
CN101230061A (zh) * 2003-10-14 2008-07-30 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
MXPA06004242A (es) * 2003-10-17 2006-06-28 Glaxo Group Ltd Antagonistas del receptor muscarinico de la acetilcolina.
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005087236A1 (en) * 2004-03-11 2005-09-22 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
AR050902A1 (es) 2004-04-27 2006-12-06 Glaxo Group Ltd Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion
EP1747219A4 (en) * 2004-05-13 2010-05-26 Glaxo Group Ltd Antagonists of muscarinic acetylcholine receptor
JP2008520579A (ja) * 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US20100329996A1 (en) * 2007-09-12 2010-12-30 Glaxo Group Limited Novel Combination of Therapeutic Agents
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
UY31637A1 (es) 2008-02-06 2009-08-03 Farmacoforos duales-antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
EP2280946B1 (en) 2008-06-05 2016-02-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
WO2010097114A1 (en) * 2009-02-26 2010-09-02 Glaxo Group Limited Novel combination of therapeutic agents
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Itk阻害剤として使用されるピリミジン誘導体
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
HRP20151017T1 (hr) 2010-09-08 2015-10-23 Glaxosmithkline Intellectual Property Development Limited Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
KR20160062179A (ko) 2013-10-17 2016-06-01 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 호흡기 질병의 치료를 위한 pi3k 억제제
WO2015173701A2 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CA3173172A1 (en) 2020-03-26 2021-09-30 Christopher D. Kane Cathepsin inhibitors for preventing or treating viral infections

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
JPH03133980A (ja) * 1989-10-19 1991-06-07 Pfizer Inc 抗ムスカリン気管支拡張剤
JPH05501554A (ja) * 1990-01-06 1993-03-25 ファイザー・インコーポレーテッド ムスカリン様レセプター拮抗薬
JPH06505718A (ja) * 1991-03-15 1994-06-30 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 新規なビシクロ及びトリシクロアミノアルコールのエステル、その製法及び医薬組成物におけるそれらの使用
WO1995015951A1 (en) * 1993-12-10 1995-06-15 Kyorin Pharmaceutical Co. Ltd. Novel imidazole derivative and process for producing the same
JPH08291141A (ja) * 1995-04-21 1996-11-05 Kotobuki Seiyaku Kk ジフェニル酢酸誘導体及びその製造法
JPH0920758A (ja) * 1995-07-06 1997-01-21 Kyorin Pharmaceut Co Ltd 新規環状ジアミン誘導体及びその製造法
WO2003033495A1 (en) * 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
WO2003078428A1 (de) * 2002-03-16 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Difurylglykolsäuretropenolester, als anticholinergika

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800482A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Olefinic derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) * 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
EP0069715B1 (en) 1981-07-08 1986-11-05 Aktiebolaget Draco Powder inhalator
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
DK172541B1 (da) 1982-10-08 1998-12-07 Glaxo Group Ltd Apparat til administrering af medikamenter til patienter og en medikamentpakning til brug i apparatet
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1998024788A1 (en) 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
PE20050327A1 (es) 2003-07-17 2005-06-08 Glaxo Group Ltd Derivados de 8-azoniabiciclo[3.2.1]octano como antagonistas de los receptores muscarinicos de la acetilcolina
PE20050711A1 (es) 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
TW200519108A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
CN101230061A (zh) * 2003-10-14 2008-07-30 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
TW200524577A (en) * 2003-11-04 2005-08-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
JP2008518939A (ja) 2004-10-29 2008-06-05 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
JP2008520579A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規m3ムスカリン性アセチルコリン受容体アンタゴニスト
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800478A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
JPH03133980A (ja) * 1989-10-19 1991-06-07 Pfizer Inc 抗ムスカリン気管支拡張剤
JPH05501554A (ja) * 1990-01-06 1993-03-25 ファイザー・インコーポレーテッド ムスカリン様レセプター拮抗薬
JPH06505718A (ja) * 1991-03-15 1994-06-30 ベーリンガー インゲルハイム コマンディトゲゼルシャフト 新規なビシクロ及びトリシクロアミノアルコールのエステル、その製法及び医薬組成物におけるそれらの使用
WO1995015951A1 (en) * 1993-12-10 1995-06-15 Kyorin Pharmaceutical Co. Ltd. Novel imidazole derivative and process for producing the same
JPH08291141A (ja) * 1995-04-21 1996-11-05 Kotobuki Seiyaku Kk ジフェニル酢酸誘導体及びその製造法
JPH0920758A (ja) * 1995-07-06 1997-01-21 Kyorin Pharmaceut Co Ltd 新規環状ジアミン誘導体及びその製造法
WO2003033495A1 (en) * 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
WO2003078428A1 (de) * 2002-03-16 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Difurylglykolsäuretropenolester, als anticholinergika

Also Published As

Publication number Publication date
EP1677795A4 (en) 2006-12-27
KR20080067023A (ko) 2008-07-17
JP5450509B2 (ja) 2014-03-26
BRPI0415361A (pt) 2006-12-12
IL188112A0 (en) 2008-03-20
NZ546312A (en) 2008-09-26
SI1677795T1 (sl) 2011-04-29
MA28110A1 (fr) 2006-08-01
AP2006003566A0 (en) 2006-04-30
WO2005037280A1 (en) 2005-04-28
US20070244150A1 (en) 2007-10-18
AP2007004238A0 (en) 2007-12-31
EA200600773A1 (ru) 2008-04-28
EA200702619A1 (ru) 2008-04-28
ES2358673T3 (es) 2011-05-12
ECSP066468A (es) 2006-11-16
US20070105895A1 (en) 2007-05-10
EP1677795B1 (en) 2011-01-05
AP2007004239A0 (en) 2007-12-31
AR046103A1 (es) 2005-11-23
TWI409060B (zh) 2013-09-21
JP2011162556A (ja) 2011-08-25
KR20080065318A (ko) 2008-07-11
TW200811172A (en) 2008-03-01
UA89734C2 (en) 2010-02-25
TW200811171A (en) 2008-03-01
IS2918B (is) 2015-01-15
CN1893948A (zh) 2007-01-10
NO20062042L (no) 2006-05-08
US7579361B2 (en) 2009-08-25
AU2004281724A1 (en) 2005-04-28
PT1677795E (pt) 2011-04-01
EA009899B1 (ru) 2008-04-28
JP2007314567A (ja) 2007-12-06
KR20060106821A (ko) 2006-10-12
PE20050963A1 (es) 2006-01-11
UA87473C2 (en) 2009-07-27
US7576096B2 (en) 2009-08-18
EA200702617A1 (ru) 2008-04-28
IL174843A0 (en) 2006-08-20
HRP20110232T1 (hr) 2011-05-31
NZ556424A (en) 2008-12-24
EA013689B1 (ru) 2010-06-30
AU2004281724B2 (en) 2010-07-15
CN101230061A (zh) 2008-07-30
AP1828A (en) 2008-02-13
US7276521B2 (en) 2007-10-02
OA13316A (en) 2007-04-13
CN101230062A (zh) 2008-07-30
EP1677795A1 (en) 2006-07-12
JP4796552B2 (ja) 2011-10-19
TW200522933A (en) 2005-07-16
EA013435B1 (ru) 2010-04-30
IL188112A (en) 2012-10-31
MXPA06004244A (es) 2006-06-28
CA2542657C (en) 2011-03-01
MY143366A (en) 2011-04-29
US20070238752A1 (en) 2007-10-11
ATE494285T1 (de) 2011-01-15
DE602004030930D1 (de) 2011-02-17
DK1677795T3 (da) 2011-04-18
JP2007277276A (ja) 2007-10-25
SG147436A1 (en) 2008-11-28
CA2542657A1 (en) 2005-04-28
CY1111364T1 (el) 2015-08-05
IS8441A (is) 2006-05-05
PL1677795T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
JP4796552B2 (ja) ムスカリン性アセチルコリン受容体アンタゴニスト
US20070135478A1 (en) Muscarnic acetylchorine receptor antagonists
AU2007203078B2 (en) Muscarinic acetylcholine receptor antagonists
RU2058985C1 (ru) Производные индола, способ их получения и фармацевтическая композиция для лечения психических расстройств на их основе
KR20070017965A (ko) 무스카린성 아세틸콜린 수용체 길항제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110705